Results Snapshot
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Mar 2026 is 40.36% vs -98.77% in Mar 2025
Consolidate Net Profit
YoY Growth in quarter ended Mar 2026 is -45.77% vs -110.62% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Mar 2026 is -40.42% vs -110.85% in Mar 2025
Interest
YoY Growth in quarter ended Mar 2026 is 66.25% vs 125.35% in Mar 2025
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Mar 2026 has improved from Mar 2025
Compare Quarterly Results Of Sichuan Biokin Pharmaceutical Co., Ltd. With
Quarterly - Net Sales
QoQ Growth in quarter ended Mar 2026 is -79.17% vs -76.03% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 40.36% vs -98.77% in Mar 2025
Quarterly - Consolidate Net Profit
QoQ Growth in quarter ended Mar 2026 is -38.54% vs -189.69% in Dec 2025
YoY Growth in quarter ended Mar 2026 is -45.77% vs -110.62% in Mar 2025
Quarterly - Operating Profit (PBDIT)
QoQ Growth in quarter ended Mar 2026 is -47.88% vs -153.49% in Dec 2025
YoY Growth in quarter ended Mar 2026 is -40.42% vs -110.85% in Mar 2025
Quarterly - Interest
QoQ Growth in quarter ended Mar 2026 is 1.53% vs 7.38% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 66.25% vs 125.35% in Mar 2025
Quarterly - Operating Profit Margin (Excl OI)
QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025
YoY Growth in quarter ended Mar 2026 has improved from Mar 2025






